Anticancer drug-induced immunomodulation and cancer therapeutics

Current Cancer Therapy Reviews

Volumn 3, Issue 3, 2007, Pages 174-193

  Mihich, Enrico ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Adriamycin; Cell antitumor effects; Cyclophosphamide; Difluoromethyl ornithine; Immunosuppression; Vinca alkaloids

Indexed keywords

5 IMINODAUNORUBICIN; ACLARUBICIN; ANTINEOPLASTIC AGENT; AUROMOMYCIN; BCG VACCINE; BLEOMYCIN; BUSULFAN; CISPLATIN; CORYNEBACTERIUM PARVUM EXTRACT; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IMATINIB; INTERLEUKIN 2; KRESTIN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN C; NOCARDIA RUBRA CELL WALL SKELETON; OXANOSINE; PICIBANIL; TAXANE DERIVATIVE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VINCA ALKALOID;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CELLULAR IMMUNITY; CHORIOCARCINOMA; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; DRUG TRANSFORMATION; FIBROSARCOMA; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; LEUKEMIA; LOW DRUG DOSE; LUNG TUMOR; LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMA; SINGLE DRUG DOSE; STOMACH CANCER; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 34547782195     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339407781368350     Document Type: Review

References (318)

1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893; 105: 497-11.
2. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmalcol Ther 1994; 64: 529-64.
3. Coley, WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the stretococcus of erysipelas and the bacillus prodigiosus). Practitioner 1909; 83: 589-613.
4. McKenzie RC, Sauder DN. Keratinocyte cytokines and growth factors - functions in skin immunity and homeostasis. Dermatol Clin 1990; 8: 649-61.
5. Mihich E, Westphal O, Luderitz O, Neter E. The tumor necrotizing effect of lipid A component of Escherichia coli endotoxin. Proc Soc Exp Biol Med 1961; 107: 816-9.
6. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666-70.
7. Usami H, Yamamoto A, Yamashita W, et al. Antitumor effects of streptococcal lipoteichoic acids on Meth A fibrosarcoma. Br J Cancer 1988; 57: 70-3.
8. Tsukgoshi S. In: Host Defense-Against Cancer and Its Potentiation. Baltimore, Univ of Tokyo Press. 1975; 365-77.
9. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcoma. J Natl Cancer Inst 1957; 18: 769-78.
10. Prehn RT. In: Mihich E Ed, Immunity, Cancer and Chemotherapy. New York, Academic Press. 1967; 265-79.
11. Klein G, Sjogren HO, Klein E, et al. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960; 20: 1561-72.
12. Mihich E. Modification of tumor regression by immunologic means. Cancer Res 1969; 29: 2345-52.
13. Mihich E, Fefer A, Eds, Report on the Biological Response Modifiers by the Subcommittee of the DCT Board of Scientific Advisors. J Natl Cancer Inst Monogr 1983; No 63.
14. Hadden JW. Immunostimulants. Trends Pharmacol Sci 1993; 14: 169-74.
15. Mihich E. Historical overview of biological response modifiers. Cancer Invest 2000; 18: 456-66.
16. Iida S, Matsuoka S, Kudo C, Moriya Y, Yoshida T, Saito M. Combination chemo-immunotherapy of murine solid tumor with OK-432, G-CSF, IL-2, and chemotherapeutics. Int J Immunopharmacol 1995; 17: 973-80.
17. Kobayashi E, Motoki K, Uchida T, Fukushima, H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 1995; 7: 529-34.
18. Utsugi T, Dinney CPN, Killion JJ, Fidler IJ. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Cancer Immunol Immunother 1991; 33: 375-81.
19. Oettgen, HF, Old LJ. In: Biologic Therapy of Cancer, DeVita Jr VT, Hellman S, Rosenberg SA Eds, Philadelphia, JB Lippincott. 1991; 87-122.
20. Mastrangelo MJ, Berd D. In: Mihich E Ed, Immunological Approaches to Cancer Therapeutics. New York, John Wiley and Sons. 1982; 75-106.
21. Morton DL, Hunt KK, Bauer RL, Lee JD. In: DeVita Jr VT, Hellman S, Rosenberg SA Eds, Biologic Therapy of Cancer. Philadelphia, JB Lippincott. 1991; 627-42.
22. Herr HW. In: DeVita Jr VT, Hellman S, Rosenberg SA Eds, Biologic Therapy of Cancer. Philadelphia, JB Lippincott. 1991: 643-50.
23. Pansadoro V, Emiliozzi P, Depaula F, et al. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). J Exp Clin Cancer Res 2003; 22: 223-7.
24. Steinbach F, Schuster F. Intravesical adjuvant chemotherapy for superficial bladder cancer - results of a survey in Saxony. Aktuelle Urol 2005; 36: 337-41.
25. Kassouf W, Kamat AM. Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 2004; 4: 1037-46.
26. Tinazzi E, Ficarra V, Simeoni S, Peterlana D, Lunardi C. Reactive arthritis following BCG immunotherapy for bladder carcinoma. Clin Rheumatol 2005; 24: 425-7.
27. Joudi FN, Smith BJ, O'Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 2006; 175: 1634-9.
28. Bevers RF, Kurth KH, Schamhart DH. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 2004; 91: 607-12.
29. Eto M, Koga H, Noma H, Yamaguchi A, Yoshikai Y, Naito S. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guerin for superficial bladder tumors. Urol Int 2005; 75: 114-8.
30. Yamada H, Luo Y, Matsumoto T, O'Donnell MA. A novel expression of macrophage derived chemokines in human bladder cancer. J Urol 2005; 173: 990-5.
31. Sanchez-Carbayo M, Urrutia M, Romani R, Herrero M, Gonzalez de Buitrago JM, Navajo JA. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Anticancer Res 2001; 21: 3041-7.
32. Watanabe E, Matsuyama H, Matsuda K, et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 2003; 52: 481-6
33. Arnold J, de Boer EC, O'Donnell MA, Bohle A, Brandau S. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother 2004; 27: 116-23.
34. Bartolome Pacheco MJ, Martinez-Taboada VM, Blanco R, Rodriguez-Valverde V, Valle JI, Lopez-Hoyos M. Reactive arthritis after BCG immunotherapy: T cell analysis in peripheral blood and synovial fluid. Rheumatology 2002; 41: 1119-25.
35. Brandau S, Riemensberger J, Jacobsen M et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001; 92: 697-702.
36. Suttmann H, Jacobsen M, Reiss K, Jocham D, Bohle A, Brandau S. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 2004; 172: 1490-5.
37. Chang SG, Lee SJ, Huh JS, Lee JH. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy. Oncol Reports 2001; 8: 257-61.
38. Vanky F, Wang P, Klein E. The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumor cells. Cancer Immunol Immunother 1992; 35: 193-8.
39. Kobayashi Y, Yoshikawa T, Watanabe N. Tumor cytostasis mediated by LPS- or PSK-activated human plastic-adherent peripheral blood mononuclear cells. Cell Immunol 1992; 144: 358-66.
40. Hirose K, Zachariae COC, Oppenheim JJ, Matsushima K. Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 1990; 9: 475-83.
41. Kim HS, Kacew S, Lee BM. In vitro chemopreventive effects of plant polysaccharides (Aloe barbadensis miller, Lentinus edodes, Ganoderma lucidum and Coriolus versicolor). Carcinogenesis 1999; 20: 1637-40.
42. Matsunaga K, Hosokawa A, Oohara M, Sugita N, Harada M, Nomoto K. Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor-β. Immunopharmacology 1998; 40: 219-30.
43. Kobayashi Y, Kariya K, Saigenji K, Nakamura K. Oxidative stress relief for cancer-bearing hosts by the protein-bound polysaccharide of Coriolus versicolor QUEL with SOD mimicking activity. Cancer Biother 1994; 9: 55-62.
44. Nio Y, Tsubono M, Tseng, CC, et al. Immunomodulation by orally administered protein-bound polysaccharide PSK ih patients with gastrointestinal cancer. Biotherapy 1992; 4: 117-28.
45. Nakajima T, Ichikawa S, Uchida S, Komada T. Effects of a protein-bound polysaccharide from a basidiomycetes against hepatocarcinogenesis induced by 3′-methyl-4-dimethylaminoazobenzene in rats. Clin Ther 1990; 12: 385-92.
46. Tsukagoshi S, Hashimoto Y, Fujii G, et al. [Review] Cancer Treat Rev 1994; 11: 131-55.
47. Kobayashi H, Matsunaga K, Fujii M. PSK as a chemopreventive agent. Cancer Epidemiol Biomarkers Prev 1993; 2: 271-6.
48. Kato M, Hirose K, Hakozaki M, et al. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother 1995,40: 152-6.
49. Jun L, Mei Z, Yuan C. Reversal of inhibition of reactive oxygen species on respiratory burst of macrophages by polysaccharide from Coriolus versicolor. Int J Immunopharmacol 1993; 15: 429-33.
50. Habelbah H, Okada F, Nakai K, et al. Polysaccharide K induces Mn superoxide dismutase (Mn-SOD) in tumor tissues and inhibits malignant progression of QR-32 tumor cells: possible roles of interferon alpha, tumor necrosis factor alpha and transforming growth factor beta in Mn-SOD induction by polysaccharide K. Cancer Immunol Immunother 1998; 46: 338-44.
51. Yefenof E, Gafanovitch I, Oron E, Bar M, Klein E. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother 1995; 41: 389-06.
52. Yefenof E, Einat E, Klein E. Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma, by polysaccharide K. Cancer Immunol Immunother 1991; 34: 133-7.
53. Liu A, Klein G, Bandobashi K, Klein E, Nagy N. SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK. Immunol Lett 2002; 80: 181-8.
54. Kariya Y, Inoue N, Kihara T, et al. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2. Immunol Lett 1992; 31: 241-5.
55. Ohno R, Yamada K, Masaoka T, et al. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 1984; 18: 149-54.
56. Hattori T, Niimoto M, Nakano A, Oride M, Takiyama W, Nishimawari K. Postoperative long-term immunochemotherapy with Mitomycin-C, PSK and FT-207 in gastric cancer patients. Jpn J Sur 1979; 9: 110-7.
57. Kano T, Kumashiro R, Tamada R, Kodama Y, Inokuchi K. Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Sur 1981; 11: 291-6.
58. Torisu M. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990; 31: 261-8.
59. Nishiwaki Y, Furuse K, Fukuoka M, et al. A randomized controlled study of PSK combined immunochemotherapy for adenocarcinoma of the lung. The Advanced Lung Cancer Immunochemotherapy Study Group. Jpn J Cancer Chemother 1990; 17: 131-6.
60. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with state II or III colorectal cancer: a randomized controlled study. Br J Cancer 2004; 90: 1003-10.
61. Umezawa I, Komiyama K, Kawakubo Y, Koyanagi N, Arai H, Nishiyama Y. Immunological studies on the antitumor effect of sporamycin, Gann 1981; 72: 598-03.
62. Ishizuka M, Fukasawa S, Masuda T, et al. Antitumor effect of bactobolin and its influence on mouse immune system and hematopoietic cells. J Antibiot 1980; 33: 1054-62.
63. Ishizuka M, Takuchi T, Masuda T, Fuksawa S, Umezawa H. Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A. J Antibiot 1981; 34: 331-40.
64. Ishizuka M. Influence of inhibitors against enzymes located on the cell surface on immune responses and its antitumor effect. Jpn J Cancer Chemother 1979; 5: 165-74.
65. Mihich E, Ehrke, MJ, Masaaki I. In: Mihich E, Sakurai Y Eds, Biological Responses in Cancer. New York, Plenum Publishing Corp. 1985; 71-93.
66. Ortaldo JR, Philips W, Wasserman K, Herberman RB. Effects of metabolic inhibitors on spontaneous and interferon-boosted human natural killer cell activity. J Immunol 1980; 125: 1839-44.
67. Mihich E, Ehrke MJ. In: DeVita VT, Heilman S, Rosenberg SA Eds, Biologic Therapy of Cancer Principles and Practice. Philadelphia, JB Lippincott Co. 1991; 776-86.
68. Komiyama K, Umezawa I, Akiyama T, Hata, T. Immunological studies on sporamycin-treated animals. J Antibiot 1979; 32: 1201-6.
69. Kataoka T, Ogihara K, Sakurai Y. Immumoprophylactic and immunotherapeutic response by concanavalin A-bound tumor vaccine enhanced by chemotherapeutic agents eliminating possible suppressors. Cancer Res 1980; 40: 3839-45.
70. Parker D, Turk JL. Potentiation of T-lymphocyte function by bleomycin. Immunopharmacology 1984; 7: 109-13.
71. Abdul Hamiel TA, Turk JL. Enhancement of interleukin 2 release in rats by treatment with bleomycin and adriamycin in vivo. Cancer Immunol Immunother 1987; 25: 245-9.
72. Morikawa. K, Hosakawa M, Hamada J, et al. Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin in a rat firbrosarcoma. Cancer Res 1985; 45: 1502-7.
73. Ehrke MJ, Mihich E, Berd D, Mastrangelo M. Effects of anticancer drugs on the immune system in man. Semin Oncol 1989; 16: 230-53.
74. Ehrke MJ, Cohen SA, Mihich E. Selective effects of Adriamycin on marine host defense systems. Immunol Rev 1982; 65: 54-78.
75. Ehrke MJ, Mihich E. In: Hadden JW, Szentivanyi A. Eds, Reficuloendoethelial System: A Comprehensive Treatise. New York, Plenum Press 1985; 309-47.
76. Mihich E. Future perspectives for biological response modifiers: A viewpoint. Semin Oncol 1986; 13: 234-54.
77. Ehrke MJ, Mihich E. In: Berkarda B, Karrer K, Mathe G Eds, Clinical Chemotherapy, Vol III Antineoplastic Chemotherapy. Suttgart, Germany Thieme-Stratton 1984; 475-99.
78. Ehrke MJ, Mihich E. In: Mitchell MS, Fahey JL Eds, Clinics in Immunology and Allergy, Vol 4, No 2, Immune Suppression and Modulation. London, Saunders. 1984; 259-77.
79. Ehrke MJ, Mihich E. In: Tapiero H, Robert F, Lampidis TJ Eds, Anti-Cancer Drugs. John Libbey Eurotext Limited. 1989; Vol 191: 129-38.
80. Mihich E. Biological response modifiers in therapeutics: potential and limitations. Cancer Detect Prev 1988; 12: 531-5.
81. Ehrke MJ, Mildch E. In: Immunopharmacology Reviews. Hadden JW, Szentivanyi A Eds, New York, Plenum Press 1996; 103-28.
82. Schwartz HS, Gtindey GB. Adriamyin and Daunorubicin: A comparison of antitumor activities and tissue uptake in mice following immumosuppression. Cancer Res 1973; 33: 1837-44.
83. Giuliani G, Casazza AM, DiMarco A. Virologic and immunologic properties and response to Daunomycin and Adriamycin of a non-regressing mouse tumor derived from MSV-induced sarcoma. Biomedicine 1974; 21: 435-39.
84. Mantovani A, Candiani P, Luini W, et al. In: Ferrone S, Gorini S, Herberman GB, et al. Eds, Current Trends in Tumor Immunology. New York, Garland 1979; 139-54.
85. Ehrke MJ, Tomazic V. Ryoyama K, Cohen SA, Mihich E. Adriamycin induced immunomodulation: Dependence upon time of administration. Int J Immunopharmacol 1983; 5: 43-8.
86. Orsini F, Pavelic Z, Mihich E. Increased primary cell mediated immunity in culture subsequent to Adriamycin or Daunorubicin treatment of spleen donor mice. Cancer Res 1977; 37: 1719-26.
87. Tomazic V, Ehrke MJ, Mihich E. Modulation of the cytotoxic response against allogeneic tumor cells in culture by Adriamycin. Cancer Res 1980; 40: 2748-55.
88. Tomazic V, Ehrke MJ, Mihich E. Augmentation of the development of immune responses of mice against allogeneic tumor cells after Adriamycin treatment. Cancer Res 1981; 41: 3370-6.
89. Maccubbin DL, Mace KF, Ehrke MJ, Mihich, E. Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res 1989; 49: 4216-24.
90. Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Mihich E. Correlation between Adriamycin-induced augmentation of interleukin 2 production and of cell mediated cytotoxicity in mice. Cancer Res 1986; 46: 54-60.
91. Ehrke MJ, Ryoyama K, Cohen SA. Cellular basis for Adriamycininduced augmentation of cell mediated cytotoxicity in culture. Cancer Res 1984; 44: 2497-04.
92. Ehrke MJ, Tomazic V, Ryoyama K, Cohen SA, Mihich E. Adriamycin induced immunomodulation: Dependence upon time of administration. Int J Immunopharmacol 1983; 5: 43-8.
93. Ho RLXMaccubbin D, Ujhazy P, et al. Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma. Oncol Res 1993a; 5: 363-72.
94. Ho RLXMaccubbin D, Zaleskis G, Wing D, Mihich E, Ehrke MJ. Development of a non-toxic adriamycin plus interleukin 2 therapy effective against both adriamycin sensitive and resistant lymphomas. Oncol Res 1993b; 5: 373-81.
95. Ryoyama K, Ehrke MJ, Mihich E. Induction of suppressor T-cells in culture. II, Modification by Adriamycin. Int J Immunopharmacol 1984; 6: 521-27.
96. Ryoyama K, Ehrke MJ, Mihich E. In: Dubois JB, Serrou B, Rosenfeld C Eds, Immunopharmacologis Effects of Radiation Therapy. New York, Raven Press 1981; 23-37.
97. Mace K, Mayhew E, Mihich E, Ehrke MJ. Alterations in murine host defense functions by Adriamycin or liposome encapsulated Adriamycin. Cancer Res 1988; 48: 130-36.
98. Santoni A, Riccardi C, Sorci V, et al. Effects of Adriamycin on the activity of mouse natural-killer cells. J Immunol 1980; 124: 2329-35.
99. Cohen SA, Salazar D, Wicher J. Adriamycin induced activation of NK activity may initially involve LAF production. Cancer Immunol Immunother 1983; 15: 188-93.
100. Maccubbin DI, Cohen SA, Ehrke MJ. Indomethacin modulation of Adriamycin induced effects on multiple cytolytic effector functions. Cancer Immunol. Immunother 1990; 31: 373-80.
101. Cohen SA, Ehrke MJ, Mihich E. In: Weber G Ed, Advances in Enzyme Regulation. New York, Pergamon Press. 1980; Vol 18, 335-46.
102. Cohen SA, Ehrke MJ, Ryoyama K, Mihich E. Augmentation of the phagocytic activity of murine spleen cell population induced by Adriamycin. Immunopharmacology 1982; 5: 75-84.
103. Mihich E. On the immunomodulating effects of anticancer drugs and their therapeutic exploitation. Jpn J Clin Oncol 2000; 30: 469-71.
104. Hattori K, Matsushita R, Kimura K, Abe Y, Nakashima E. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. Biol Pharm Bull 2001; 24: 1214-17.
105. Leung KH, Mihich E. Prostaglandin modulation of development of cell-mediated immunity in culture. Nature, 1980; 288: 597-600.
106. Leung KH, Mihich E. Effects of prostaglandins on the development of cell-mediated immunity in culture and on the cytolytic activity of in vivo-generated effector cells. Int J Immunopharmacol 1982; 4: 205-17.
107. 2. J Immunol 1982; 129: 1742-7.
108. Henney CS, Bourne HR, Lichtenstein LM. The role of cyclic 3′, 5′ adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol 1972; 108: 1526-34.
109. Roder JC, Klein M. Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides. J Immunol 1970; 123: 2785-90.
110. Brunda M, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980; 124: 2682-87.
111. Schultz RM, Paulidis NA, Stylos WA, Chirigos MA. Regulation of macrophage tumoricidal function: a role for prostaglandins of the E series. Science 1980; 202: 320-1.
112. Lieb J. The immunostimulating and antimicrobial properties of lithium and antidepressants. J Infect 2004; 49: 88-93.
113. Lieb J. Antidepressants, eicosanoids and the prevention and treatment of cancer. A Review. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 233-9.
114. Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES. Doxorubicin induces specific immune functions and cytokine expression inperitoneal cells. Cancer Immunol Immunother 2003; 52: 463-72, DOI 10.1007/ s00262-003-0391-x.
115. Terabe M, Matsui S, Park J-M, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block Cytotoxic T Lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-52.
116. Ostrand-Rosenberg S, Sinha P, Clements V. Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immuno-surveillance against primary tumors and metastatic disease. Cancer Immunol Immunother 2004; 53: 86-91
117. Maccubbin DL, Wing KR, Mace KF, Ho RL,XEhrke, MJ, Mihich E. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res 1992; 52: 3572-6.
118. Ehrke MJ, Ho RL,XMihich E. In: Torisu M, Yoshida T Eds, Proc In: Symposium on New Horizons in Tumor Immunotherapy. Amsterdam, Elsevier 1989; 467-75.
119. Mantovani A, Candiani P, Luini W, et al. In: Ferrone S, Gorini S, Herberman GB et al Eds, Current Trends in Tumor Immunology. New York, Garland 1979; 139-54.
120. Mantovani A, Polentarutti N, Luini W, et al. Role of host defense mechanisms in the antitumor activity of Adriamycin and daunomycin in mice. J Natl Cancer Inst 1979; 63: 61-9.
121. Allavena P, Damia G, Colombo T, et al. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cell Immunol 1989; 120: 250-8.
122. Fuji H, Mihich E, Pressman D. Differential tumor immunogenicity of L1210 and its Sublines. 1. Effect of an increased antigen density on tumor cell surfaces on primary B-cell responses in vitro. J Immunol 1977; 119: 983-6.
123. Ehrke MJ, Verstovsek S, Zaleskis G, et al. Demonstration of long-term specific Anti-primary EL4 lymphoma immunity in 2-year old cured mice. Cancer Immunol Immunother 1996; 42: 221-30.
124. Zaleskis G, Ho RL,XDiegelman P, et al. Intracellular doxorubicin kinetics in lymphoma cells and lymphocyres infiltrating the tumor area in vivo: A flow cytometric study. Oncol Res 1994; 6: 183-94.
125. Zagozdzon R, Golab J, Stoklosa T, et al. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer 1998; 77: 720-7.
126. Ewens A, Luo L, Berleth E, et al. Doxorubicin plus Interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res 2006; 66: 5419-26.
127. Ujhazy P, Chen Y, Fredericks W, et al. The relationship between multidrug resistance and tumor necrosis factor resistance in an EL-4 cell line model. Cancer Commun 1990; 2: 181-8.
128. Ehrke MJ, Verstovsek S, Ujhazy P, et al. Doxorubicin plus tumor necrosis factor α combination treatments in ELA-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother 1998; 45: 287-98.
129. Ehrke MJ, Verstovsek S, Maccubbin DL, et al. Protective specific immunity induced by Doxorubicin plus TNF-α combination treatment of EL4 lymphoma-bearing C57BL/6 mice. Int J Cancer 2000; 87: 101-9.
130. Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better. Int J Oncol 2001; 18: 417-24.
131. Shiozaki K, Harada N, Greco WR, et al. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother 2006; 55: 140-50.
132. Zhou H, Seqeira M, Goad ME, et al. Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy. Clin Immunol 2001; 101: 303-14.
133. Runyon K, Lee K, Zuberek K, Collins M, Leonard JP, Dunussi-Joannopoulos K. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of minor-specific memory responses. Blood 2001; 97: 2420-6.
134. Lumsden AJ, Codde JP, Van der Medie PH, Gray BN. Immunohistochemical characterization of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma. Anticancer Res 1996; 16: 1145-54.
135. Maccubbin D, Whitman J, Taniguchi N, et al. Comparison of Adriamycin induced immunomodulation with that of the noncardiotoxic anthracyclinc 5-iminodaunorubicin. Int J Immunopharmacol 1988; 10: 317-23.
136. Tong GL, Henry DW, Acton EM. 5-Iminodaumorubicin. Reduced cardiotoxic properties in an antitumor anthracycline. J Med Chem 1979; 22: 36-9.
137. Herman EH, Rahman A, Ferrans VJ, et al. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 1983; 43: 5427-32.
138. Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, Gabizon A. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubiein with soluble and liposomal interleukin 2. Clin Cancer Res 1999; 5: 687-93.
139. Yakushiji T, Yomemura K, Nishidi K, Takagi, K. In vivo tumouricidal effect of T lymphocytes activated by liposomes containing adriamycin on chemically-induced rat malignant fibrous histiocytoma. Anticancer Res 1997; 17; 4347-54.
140. Both JA, Eilber FR, Morton DL. Effect of Adriamycin and high-dose methotrexate chemotheraphy in vivo and in vitro cell-mediated immunity in cancer patients. Cancer 1978; 41: 814-19.
141. Kleinerman ES, Zwelling LA, Schwartz R, et al. Effect of L-phenylalanine mustard, Adriamycin and actinomycin D and 4′-(9-acridinylamino) methanesulfon-m-anisidide on naturally occurring human spontaneous monocyte-mediated cytotoxicity. Cancer Res 1982; 42: 1692-5.
142. Arinaga S, Akiiyoshi T, Tsuji H. Augmentation of the cell-mediated cytotoxic response induced in mixed cell culture by Adriamycin. Jpn J Cancer Res 1985; 76: 414-19.
143. Arinaga S, Akiyoshi T, Tsuji H. Augmentation of the generation cell mediated cytotoxicity after a single dose of Adriamycin in cancer patients. Cancer Res 1986; 46: 4213-16.
144. Paciucci PA, Bekesi JG, Ryder JS, Odchimar R, Chahinian PA, Holland JF. Immunotherapy with IL2 by constant infusion and weekly doxorubicin. Am J Clin Oncol 1991; 14: 341-8.
145. LeCesne A, Vassal G, Farace F, et al. Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?J Immunother 1999; 22: 268-77.
146. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokines system in diverse forms of macrophage activation and polarization. Trens Immunol 2004; 25: 677-86.
147. Mokyr MB, Dray S. Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy. Cancer Invest 1987; 5: 31-38.
148. Kempf RA, Mitchell MS. Effects of chemotherapeutic agents on the immune response I. Cancer Invest 1984; 2: 459-66.
149. Kempf RA, Mitchell MS. Effects of chemotherapeutic agents on the immune response II. Cancer Invest 1985; 3: 23-33.
150. Hengst JDC, Kempf RA. In: Mitchell MS, Fahey JL Eds, Clinics in Immunology and Allergy. Vol 4, No 2, Immune Suppression and Modulation. London, Saunders 1984; 199-216.
151. Mokyr MB, Hengst JCD, Dray S. The role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. Cancer Res 1982; 42: 974-9.
152. Mokyr MB, Colvin M, Dray S. Cyclophosphamde-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor. Int J Immunopharmacol 1985; 7 111-22.
153. Berd D, Maguire HC Jr, Mastrangelo MJ. Potentiation of human cell mediated immunity by low dose cyclophosphamide. Cancer Res 1984; 44: 5439-43.
154. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+subset. Cancer Res 1987; 47: 3317-21.
155. Berd D, Mastrangelo MJ. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 1988; 6: 337-49.
156. Mitchell MS, Kempf RA, Harel W, et al. Effectiveness and tolerability of low dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma. J Clin Oncol 1988; 6: 409-24.
157. Tuttle TM, Fleming MF, Hogg PS, Inge TH, Bear HD. Low-dose cyclophosphamide overcomes metastasis-induced immunosuppression. Ann Surg Oncol 1994; 1: 53-8.
158. Krawczyk CM, Verstovsek S, Ujhazy P, Maccubbin D, Ehrke MJ. Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor α combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother 1995; 40: 347-57.
159. Berd D, Maguire HC Jr, Mastrangelo MJ. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Cancer Res 1984; 44: 1275-80.
160. Ehrke MJ, Verstovse S, Krawczyk CM, et al. Cyclophosphamide plus tumor necrosis factor-α chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer 1995; 63: 463-71.
161. Mastrangelo MJ, Maguire HC Jr, Sato T, Nathan FE, Berd D. Active specific immunization in the treatment of patients with melanoma. Semin Oncol 1996; 23: 773-81.
162. Binotto G, Tretin L, Semenzato G. Ifosfamide and cyclophosphamide: effects on immunosurveillance. Oncology 2003; 2: 17-20.
163. Ames IH. Chemoimmunotherapy of murine mammary adenocarcinomas. Anticancer Res 2004; 24: 2249-56.
164. Cowens JW, Ozer H, Ehrke MJ, Greco WR, Colvin M, Mihich E. Inhibition of the development of suppressor cells in culture by 4-hydroperoxycyclophosphamide. J Immunol 1984; 132: 95-100.
165. Ozer H, Cowens JW, Colvin M, Nussbaum-Blumenson A, Sheedy D. In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. J Exp Med 1982; 155: 276-90.
166. Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006; 16: 141-6.
167. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+subset. Cancer Res 1987; 47: 3317-21.
168. Ye Q-W, Mokyr MB. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor. Cancer Res 1984; 44: 3873-79.
169. Morikawa K, Hamada J-I, Itaya T, et al. Modification of regression of virally xenogenized tumor cells by cyclophosphamide and busulfan. Cancer Immunol Immunother 1988; 26: 18-22.
170. Ehrke MJ, Mihich E. Effects of anticancer agents on immune responses. Trends Pharmacol Sci 1985; 6: 412-17.
171. Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep 1981; 65(suppl 3): 89-95.
172. Bagley CM Jr, Bostick FW, DeVita VT Jr. Clinical pharmacology of cyclophosphamide. Cancer Res 1973; 33: 226-33.
173. Chabner BA, Myers CE. In: DeVita VT Jr, Hellman S, Rosenberg SA Eds, Cancer Principles and Practive of Oncology. Philadelphia, Lippincott 1985; 287-328.
174. Turk JL, Poulter LW. Selective depletion of lymphoid tissue by cyclophosphamide. Clin Exp Immunol 1972; 10: 285-96.
175. Lagrange PH, Mackaness GB, Miller TE. Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide. J Exp Med 1974; 139: 1529-38.
176. Askenase PW, Hayden BJ, Gershon RK. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 1975; 141: 697-702.
177. Shand FL. The capacity of microsomally-activated cyclophosphamide to induce immunosuppression in vivo. Immunology 1978; 35: 1017-25.
178. Shand FL, Liew FY. Differential sensitivity to cyclophosphamide of helper T cells for humoral responses and suppressor T cells for delayed-type hypersensitivity. Eur J Immunol 1980; 10: 480-3.
179. Diamantstein T, Klos M, Hahn E, et al. Direct in vitro evidence for different susceptibilities to 4-hydroperoxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: A possible explanation for the inverse action of cyclophosphamide on humoral and cell-mediated immune responses. J Immunol 1981; 126: 1717-19.
180. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4€D25-regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 336-44.
181. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG. Down regulation of T-cell-derived EL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharm 2001; 1: 307-19.
182. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG. Th2/Th1 switch induced by a single low-dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 2002; 50: 588-96.
183. Rabinovich GA, Rubinstein N, Matar P, Rozados V, Gervason S, Scharovsky OG. The antimetastatic effect of a single low dose of cyclophosphamide involves modulation of galectin-1 and Bcl-2 expression. Cancer Immunol Immunother 2002; 50: 597-603.
184. Zacarias Fluck MF, Rico MJ, Gervasoni SI, et al. Low dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model. Cancer Immunol Immunother 2007; 56: 237-48.
185. Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4€D25+T cells. Blood 2007; 109: 2058-65.
186. Ye QW, Mokyr MB. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor. Cancer Res 1984; 44: 3873-9.
187. Mokyr MB, Ye QW. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor. Cancer Res 1985; 45: 4932-9.
188. Mokyr MB, Rubin M, Newell KA, Prokhorova A, Bluestone JA. Involvement of TCR-V beta 8.3cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan. J Immunol 1993; 151: 4838-46.
189. Mokyr MB, Prokhorova A, Rubin M, Bluestone JA. Insight into th emechanisms of TCR-V beta 8/CD8+T cell-mediated MOPC-315 tumor eradication. J Immunol 1994; 153: 3123-34.
190. Gorelik L, Prokhorova A, Mokyr MB. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother 1994; 39: 117-26.
191. Weiskirch LM, Bar-Dagan Y, Mokyr MB. Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol Immunother 1994; 38: 215-24.
192. Copelan EA. Conditioning regimens for allogeneic bone marrow transplantation. Blood Rev 1992; 6: 234-42.
193. Massenkeil G, Nagy M, LeCoutre P, et al. Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD. Hematol J 2004; 5: 395-402.
194. Mizushima Y, Sendo F, Takeichi N, Hosohawa M, Kobayashi H. Enhancement of antitumor transplantation resistance in rats by appropriately timed administration of busulfan. Cancer Res 1981; 41: 2917-21.
195. Nagarkatti M, Toney DM, Nagarkatti PS. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res 1989; 49: 6587-92.
196. Nagarkatti M, Seth A, Nagarkatti PS. Chemotherapy of mice bearing syngeneic tumors with 1,3-bis (2-choroethyl)-1-nitrosourea is effective only in normal, but not in irradiated or nuce, mice: role of L3T4+(CD4)-and Lyt-2+(CD8)+T cells. Cell Immunol 1988; 115: 383-92.
197. Selvan RS, Nagarkatti PS, Nagarkatti M. Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+T helper and CD8+T cytotoxic cells. Int J Cancer 1990; 45: 1096-104.
198. Selvan RS, Nagarkatti PS, Nagarkatti M. Characterization of T lymphocyte clones isolated from BCNU-cured LSA mice. Int J Cell Cloning 1991; 9: 594-605.
199. Nagarkatti K Nagarkatti PS, Kaplan AM. Differential effect of BCNU on T cell, macrophage, natural killer and lymphokines-activated killer cell activities in mice bearing a syngeneic tumor. Cancer Immunol Immunother 1988; 27: 38-46.
200. Nagarkatti M, Nagarkatti PS, Kaplan AM. Differential effects of BCNU on T cell, macrophage, natural killer and lymphokines-activated killer cell activities in mice bearing a syngeneic tumor. Cancer Immunol Immunother 1988; 27: 38-46.
201. Farone AL, Cox D-C. 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU)/ interleukin-2 chemoimmunotherapy of Murine L1210 leukemia. Cancer Immunol Immunother 1992; 34: 279-81.
202. Acerbis G, Cleris L, Rodolfo M, Parmiani G, Formelli F. Post surgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumor. Cancer Immunol Immunother 1992; 34: 383-8.
203. Spreafico F, Vecchi A. In: Mihich E, Sakurai Y Eds, Biological Responses in Cancer. Immunomodulation by Anticancer Drugs. New York, Plenum Press 1985; Vol 3, 131-54.
204. Schlaefli E, Ehrke MJ, Mihich E. The effects of dichlorotansdihydroxy-bis-isopropyl-amine-platinum IV on the primary cell-mediated cytotoxic response. Immunopharmacology 1983; 6: 107-22.
205. Kleinerman ES, Zwelling LA. In: Mitchell MS, Fahey JL Eds, Clinics in Immunology and Allergy, No 2, Immune Suppression and Modulation, London, Saunders 1984; Vol 4, 279-94.
206. Kleinerman ES, Zwelling LA, Muchmore AV. Enhancement of naturally occurring human spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Cancer Res 1980; 40: 3099-102.
207. Nio Y, Hirahara N, Minari Y, et al. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface. Anticancer Res 2000; 20: 3293-9.
208. Hayashi H, Nio Y, Kawabata K, Araya S, Imamura M. Cisdiamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-e and increases susceptibility and binding of tumor cells to various cytotoxic effector cells. J Surg Oncol 1996; 62: 162-70.
209. Gold JE, Bleiweiss IJ, Goldfarb AB, et al. Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocyres with potentiation by cis-diammine-dichloroplatimun (II). J Surg Oncol 1994; 55: 222-8.
210. Gold JE, Master TR, Bloom ND, et al. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum (II). J Surg Oncol 1995; 58: 212-21.
211. Gold JE, Master TR, Babbit B, et al. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumor targets with potential by cis-diamminedichlomplatinum (II). Br J Urol 1995; 76: 115-22.
212. Singh RK, Sodhi A, Singh SM. Production of interleukin-1 and tumor necrosis factor by cisplatin-treated murine peritoneal macrophages. Nat Immun Cell Growth Regul 1991; 10: 105-16.
213. Gupta P, Sodhi A. Increased release of interleukin-1 from mouse peritoneal macrophages in vitro after cisplatin treatment. Int J Immunopharmacol 1987; 9: 385-8.
214. Suresh A, Sodhi A. Production of interleukin-1 and tumor necrosis factor by bone marrow-derived macrophages: effect of cisplatin and lipopolysaccharide. Immunol Lett 1991; 30: 93-100.
215. Allavena P, Pirovano P, Bonnazzi C, Colombo N, Mantovani A, D'Inacalci M. In vitro and in vivo effects of cisplatin on the generation of lymphokines-activated killer cells. J Natl Cancer Inst 1990; 82: 139-42.
216. Nielsen OH, Vainer B, Rask-Madsen J. Review article: The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15: 1699-708.
217. Schwartz RS. In: Rapaport FT, Dausset J Eds, Human Transplantation. New York, Grune Stratton 1968; 440-71.
218. Chanmougan D, Schwartz RS. Enhancement of antibody synthesis by 6-mercaptopurine. J Exp Med 1966; 124: 363-78.
219. Borel Y, Schwartz RS. Inhibition of immediate and delayed hypersensitivity by 6-mercaptopurine. J Immunol 1964; 92: 754-61.
220. Borel Y, Fauconnet M, Miescher PA. Effect of 6-mercaptopurine on different classes of antibody. J Exp Med 1965; 122: 263-75.
221. Drossler K, Klima F, Ambrosius H. The influence of cyclophosphamide and 6-mercaptopurine on the IgG1 immune response in guinea pigs. Immunology 1981; 44: 61-6.
222. Medzihradsky JL, Hollowell RP, Elion GB. Differential inhibition by azathioprine and 6-mercaptopurine of specific suppressor T cell generation in mice. J Immunopharmacol 1981; 3: 1-16.
223. Kashida T, Narasaki N, Sakai A, Tsnjihara K, Tsuzurahara K, Takeyama S. Augmentation of tumor immunity by 6-mercaptopurine (6-MP) and its analogs in the double grafted tumor system in mice. Biol Pharm Bull 1995; 18: 1492-7.
224. Kashida T, Naarasaki N, Tsujihara K, Naito K, Takeyama S. Augmentation of sinecomitant immunity in mice by gamma-(9H-purine-6-y1) thiomethyl L-glutamate (6-MPG), a water-soluble derivative of 6-mercaptopurine. Biol Pharm Bull 1998; 21: 16-21.
225. Kashida T, Narasaki N, Tsujihara K, Naito K, Takeyama S. Augmentation of tumor immunity by 6-MPG, a water-soluble derivative of 6-mercaptopurine, in mice. Int J Immunopharmacol. 1996; 18: 311-9.
226. Gibbons JJ, Lucas J. Immunomodulation by low-dose methotrexate I. Methotrexate selectivity inhibits Lyt-2+cells in murine acute graft-versus host reaction. J Immunol 1989; 142: 1867-73.
227. Weinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologic effects of methotrexate in psoriasis. J Invest Dermatol 1990; 95: 49S-52S.
228. Constantin A, Loubet-Lescoulie P, Lambert N, et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 1998; 41: 48-57.
229. Cohen CJ, Thomas GM, Thigpen JT. In: Holland JF, Bast, RC, Morton DL, Frei III E, Kufe DW, Weichselbaum RR Eds, Cancer Medicine 4th Edition. Baltimore, William Wilkins 1997; 2337-45.
230. Matheson DS, Green B, Friedman SJ, et al. Studies on the mechanism of activation of human natural killer function by interferon and inhibitors of thymidylate synthesis. Cell Immunol 1988; 111: 118-25.
231. Claessen AME, Vaister H, Bril H, et al. Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation. Cancer Immunol Immunother 1989; 28: 131-35.
232. Klein HO, Golbach G, Voigt P, Coerper C, Bernhardt C. Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer. J Cancer Res Clin Oncol 1991; 117: S214-S220.
233. Furukawa T, Kubota T, Watanabe M, et al. Immunochemotherapy prevents human colon cancer metastases after orthotopic onplantation of histologically-intact tumor tissue in nude mice. Anticancer Res 1993; 13: 287-92.
234. Yang S, Haluska FG. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-medicated pathways. J Immunol 2004; 172: 4599-608.
235. Ahmed SU, Okamoto M, Oshikawa T, et al. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunotherapy 2004; 27: 432-41.
236. Margreiter R, Fischer M, Roberts K, et al. Gemcitabine - a novel immunosuppressive agent - prevents rejection in a rat cardiac transplantation model. Transplantation 1999; 68: 1051-3.
237. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1CD11b+myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Res 2005; 11: 6713-21.
238. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005; 54: 915-25.
239. Shek PN, Coons AH. Effect of colchicines on the antibody response. I. Enhancement of antibody formation in mice. J Exp Med 1978; 147: 1213-27.
240. Kataoka Tr Oh-Hashi F, Sakurai Y, Ogihara K. Effect of antineoplastic agents on the induction of suppressor macrophages by concanavalin A-bound tumor vaccine. Cancer Res 1981; 41: 5151-7.
241. Riccardi C, Bartocci A, Puccetti P, Spreafico F, Bonmassar E, Goldin A. Combined effects of antineoplastic agents and antilymphoma allograft reactions. Eur J Cancer 1980; 16: 23-33.
242. Ryoyama K, Mace K, Ehrke MJ, Mihich E. The differential sensitivity of T-cell immune functions to vincristine and vinblastine. Int J Immunopharmacol 1982; 4: 187-93.
243. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Ind J Cancer 1997; 73: 309-16.
244. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional. maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
245. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997; 3: 483-90.
246. Mullins DW, Martins RS, Burger CJ, Elgert KD. Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation. J Leuk Biol 2001; 69: 129-37.
247. Perera PY, Mayadas TN, Takeuchi O. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 2001; 166: 574-81.
248. Moos PJ, Muskardin DT, Fitzpatrick FA. Effect of taxol and taxotere on gene expression in macrophages: Induction of the prostaglanding H synthase-2 isoenzyme. J Immunol 1999; 162: 467-73.
249. 22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of Taxol. J Immunol 2001; 166: 11-14.
250. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 2001; 7: 232-6.
251. Carboni JM, Singh C, Tepper MA. Taxol and lipopolysaccharide activation of a murine macrophage cell line and induction of similar tyrosine phosphoproteins. J Natl Cancer Inst Monogr 1993; 15: 95-101.
252. Perera PY, Vogel SN, Detore GR, Haziot A, Goyert SM. CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. J Immunol 1997; 158: 4422-29.
253. Manthey CL, Perera PY, Salkowski CA, Vogel SN. Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 1994; 152: 825-31.
254. Moos PJ, Muskardin DT, Fitzpatrick FA. Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme. J Immunol 1999; 162: 467-73.
255. Manthey CL, Perera P-Y, Salkowski CA, Vogel SN. Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 1994; 152: 825-31.
256. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999; 162: 6811-8.
257. Kalechman Y, Shani A, Dovrat S, et al. The antitumoral effect of the immunomodulator AS101 and paclitaxel. (Taxol) in a murine model of lung adenocarcinoma. J Immunol 1996; 156: 1101-09.
258. Sredni B, Caspi RR, Klein A, et al. A new immunomodulating compound (AS101) with potential therapeutic application. Nature 1987; 330: 173-6.
259. Machiels J-PH, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines n HER-2/neu tolerized mice. Cancer Res 2001; 61: 3689-97.
260. Eralp Y, Wang XWang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004; 6: R275-83.
261. Perera PY, Qureshi N, Vogel SN. Paclitaxel (Taxol)-induced NF-κB translocation in murine macrophages. Infect Immun 1996; 64: 878-84.
262. Jun CD, Choi BM, Kim HM, Chung HT. Involvement of protein kinase C during taxol-induced activatin of murine peritoneal macrophages. J Immunol 1995; 154: 6541-7.
263. Manthey CL, Brandes ME, Perera PY, Vogel SN. Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages. J Immunol 1992; 149: 2459-65.
264. Ding A, Sanchez E, Nathan CF. Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J Immunol 1993; 151: 5596-602.
265. Lee LF, Schuerer-Maly CC, Lofqist AK. Taxol-dependent transcriptional activation of IL-8 expression in a subset of human ovarian cancer. Cancer Res 1996; 56: 1303-08.
266. Allen JN, Moore SA, Wewers MD. Taxol enhances but does not induce interleukin-1 beta and tumor necrosis factor-alpha production. J Lab Clin Med 1993; 122: 374-81.
267. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999; 162: 6811-18.
268. White CM, Martin BK, Lee LF, Haskill JS, Ting JP. Effects of pacliaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes and breast cancer cells. Cancer Immunol Immunother 1998; 46: 104-12.
269. Tong AW, Seamour B, Lawson JM, et al. Cellular immune profile of patients with advanced cancer before and after taxanes treatment. Am J Clin Oncol 2000; 23: 463-72.
270. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Brit J Cancer 2002; 87: 21-7.
271. Dredge K, Marriott JB, Todryk SM, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002; 168; 4914-19.
272. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 2004; 22: 3212-14.
273. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269-76.
274. Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopolesis. Blood 2005; 105: 3833-40.
275. Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Tahlidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther 2004; 4: 1963-70.
276. DiFabio S, Trabattoni D, Geraci A, et al. Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys. J Med Primatol 2000; 29: 1-10.
277. Dredge K, Marriot JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 2002; 22: 425-37.
278. Appel S, Boehmler AM, Grunebach F, et al. Imatinib mesylate affects the development and fraction of dendritic cells generated from CD344+peripheral blood progenitor cells. Blood 2004; 103: 538-44.
279. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473-9.
280. Holtta E, Janne J, Hovi T. Suppression of the formation of polyamines and macromolecules by DL-α-difluoromethylornithine and methylglyoxal bis(guaylhydrazoe) in phytohaemagglutinin-activated human lymphocytes. Biochem J 1979; 178: 109-17.
281. Ehrke MJ, Porter CW, Eppolito C, Mihich E. Selective modulation by -α-difluoromethylornithine of T-lymphocyte and antibody-mediated cytotoxic responses to mouse tumor allografts. Cancer Res 1986; 46:2798-803.
282. Bowlin TL, McKown BJ, Dais GF, Sunkara PS. Effect of polyamine depletion in vivo by DL-alpha-difluoromethylornithine on functionally distinct populations of tumoricidal effector cells in normal and tumor-bearing mice. Cancer Res 1986; 46: 5494-8.
283. Bowlin TL, McKown BJ, Sunkara PS. Increased ornithine decarboxylase activity and polyamine biosynthesis are reqired for optimal cytolytic T lymphocyte induction. Cell Immunol 1987; 105: 110-7.
284. Bowlin TL, Hoeper BJ, Rosenberger AL, Davis GF, Sunkara PS. Effects of three irreversible inhibitors of ornithine decarboxylase on macrophage-mediated tumoricial activity and antitumor activity in B16F1 tumor-bearing mice. Cancer Res 1990; 50: 4510-4.
285. Schall RP, Sekar J, Tandon PM, Susskind BM. Difluoromethylornithine (DFMO) arrests murine CTL development in the late, pre-effector stage. Immunopharmacology 1991; 21: 129-43.
286. Nicolin A, Vadlamudi S, Goldin A. Increased immunogenicity of drug-resistent L1210 leukemias in CDF1 mice. Arch Ital Patol Clin Tumori 1970; 13: 125-33.
287. Nicolin A, Vadlamudi S, Goldin A. Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res 1972; 32: 653-7.
288. Mihich E, Kitano M. Differences in the immunogenicity of leukemia L1210 sublines; in DBA/2 Mice. Cancer Res 1971; 31: 1999-03.
289. Kitano M, Mihich E, Pressman D. Antigenic differences between Leukemia L1210 and a subline resistant to methylglyoxalbis (guanylhydrazone). Cancer Res 1972; 32: 181-6.
290. Fuji H, Mihich E. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaqe assay. Cancer Res 1975; 35: 946-52.
291. Fuji H, Mihich E, Pressman D. Differential tumor immunogenicity of L1210 and it sublines. II. An increased expression of tumor-associated antigens on subline cells recognized by serological and transplantation methods. J Natl Cancer Inst 1979; 62: 1503-10.
292. Bonmassar E, Testorelli C, Franco P, Goldin A, Cudkowicz G. Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs. Cancer Res 1975; 35: 1957-62.
293. Nicolin A, Sprafico F, Bonmassar E, Goldin A. Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo. J Natl Cancer Inst 1976; 56: 89-93.
294. Houchens DP, Bonmassar E, Gaston MR, Kende M, Goldin A. Drug-mediated immunogenic changes of virus-induced leukemia in vivo. Cancer Res 1976; 36: 1347-52.
295. Romani L, Fioretti MC, Bonmassar E. In vitro generation of primary cytotoxic lymphocytes against L5178 Y leukemia antigenically altered by 5-(3,3′-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo. Transplantation 1979; 28: 218-22.
296. Fioretti MC, Romani L, Bonmassar E. Antigenic changes related to drug action. Prog Clin Biol Res 1983; 132B: 435-45.
297. Fioretti MC, Bianchi R, Romani L, Bonmassar E. Drug-induced immunogenic changes of murine leukemia cells: dissociation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst 1983; 71: 1247-51.
298. Giampietri A, Fioretti MC, Goldin A, Bonmassar E. Durg-mediated antigenic changes in murine leukemia cells: antagonistic effects of qinacrine, an antimutagenic compound. J Natl Cancer Inst 1980; 64: 297-01.
299. D'Atri S, Marini S, Tentori L, Tricarico M, Fuggetta MP, Bonmassar E. Drug-mediated increase of susceptibility of human lung cancer to NK or LAK effector cells. Immunopharmacology 1991; 21: 199-210.
300. Prete SP, Aqino A, Masci G, et al. Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil. J Pharmacol Exp Ther 1996; 279: 1574-81.
301. Cappelletti D, Cardillo A, Bonanno E, et al. Drug-induced modulation of carcinoembryonic antigen (CEA) expression in neoplastic cells from a patient with rectal cancer. J Exp Clin Cancer Res 2000; 19: 467-9.
302. Correale P, Cusi MG, Del Vecchio MT, et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol 2005; 175: 820-8.
303. Aqino A, Prete SP, Greiner JW, et al. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 1998; 4: 2473-81.
304. Correale P, Aqino A, Giuliani A, et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-AO02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003; 104:437-45.
305. Prete SP, Cappelletti D, Baier S, et al. Pharmacological modulation of carcinoembryonic antigen in human cancer cells: studies with staurosporine. Int Immunopharm 2002; 2: 641-51.
306. Aqino A, Formica V, Prete SP, et al. Drug-induced increase of carcinoembryonic antigen expression in cancer cells. Pharmacol Res 2004; 49: 383-96.
307. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
308. Storkus WJ, Falo Jr LD. A class of cell-killing chemotherapeutic agents seems to have an additional benefit. The drugs help prompt the immune system to turn against the tumor. Nat Med 2007; 13: 28-30.
309. Mihich E. Cellular immunity for cancer chemoimmunotherapy - an overview. Cancer Imunol Immunother 2003, 52: 661-62.
310. Petersson M, Charo J, Salazar-Onfray F, et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 1998; 161: 2099-105.
311. Serafini P, Santo C, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 2004; 53: 64-72.
312. Shevach EM. Fatal attraction: tumors beckon regulatory T cells. Nat Med 2004; 10: 900-01.
313. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
314. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 117-58.
315. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 53: 904-10.
316. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
317. Lollini P-L, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6: 204-16.
318. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963-70.